<DOC>
	<DOCNO>NCT00607451</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetic pharmacodynamic effect single dos Neu-120 Parkinson 's disease patient levodopa-induced dyskinesia .</brief_summary>
	<brief_title>Safety , Tolerability , PK PD Study Neu-120 Treatment Levodopa-induced Dyskinesia</brief_title>
	<detailed_description>Parkinson 's disease progressive neurological disorder characterize tremor , bradykinesia , rigidity , gait postural instability variety nonmotor symptom . While levodopa effectively alleviate symptom Parkinson 's disease restore motor function , within 3 5 year majority Parkinsonian patient develop levodopa-induced side effect , mainly dyskinesia ( involuntary uncontrolled movement twist hand limb ) wearing ( progressive shorten therapeutic response duration ) . Dyskinesias disable side effect long term levodopa therapy Parkinsonian patient . There currently approve drug levodopa-induced dyskinesia . The effect three single ascend dos orally administer Neu-120 evaluate double blind placebo control crossover proof concept study . Following 1-day screen visit , patient randomize receive three single ascend dos Neu-120 placebo . Patients admit clinic even prior visit five occasion , separate 7 ( -3 ) day . Levodopa challenge perform baseline ( visit 1 ) treatment visit withdrawal antiparkinsonian medication 12 hour . Blood sample take measurement Neu-120 levodopa plasma level . Primary parameter improvement levodopa-induced dyskinesia . Secondary parameter safety , tolerability , pharmacodynamic assessment dyskinesias motor function , Neu-120/levodopa pharmacokinetic profile correlation pharmacodynamic effect Neu-120/levodopa level .</detailed_description>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Male female patient age 3080 year old ( age include ) . Use adequate effective birth control measure ( include rhythm method ) study period 3 month end study men woman childbearing potential within two year menopause ( woman perform urine pregnancy test screen visit ) Idiopathic Parkinson Disease ( UK PD Society Brain Bank Clinical Diagnosis Criteria ) diagnose least 3 year . Hoehn Yahr `` ON '' time ( good medication response ) stage IIIII . Treatment levodopa optimize dose alone dopamine agonist , MAOB inhibitor COMT inhibitor stable least 4 week prior visit 1 Use hypnotic , sedative , betablockers , anxiolytic antidepressant stable least 4 week prior visit 1 . A minimal baseline Levodopa induce dyskinesia score 2 question 32 ( dyskinesias present 25 % waking day ) ; score 2 question 33 UPDRS ( severely disable dyskinesia ) Part IV ( historical information ) . A minimal basal level motor fluctuation 25 % cumulative hour OFF time every day wake hour UPDRS Part IV ( minimal score 1 question 39 UPDRS , historical information ) . Patients least 33 % motor improvement response levodopa challenge dose base UPDRS motor score ( Part III ) visit 1 . Patients experience peakdose dyskinesia score least 2 2 ( â‰¥2 ) area ( score least 4 ) modify AIMS scale response levodopa challenge dose visit 1 . Patients must good general health determine medical history , physical examination , ECG , vital sign , serum biochemistry haematology . Patients must sign informed consent form . Patient Nonidiopathic Parkinson 's disease ( e.g druginduced form secondary atypical Parkinsonism ) . Neuropsychiatric exclusion : dementia ( Mini Mental State Exam &lt; 23 , history presence psychosis ( visual hallucination take dopamine agonist ) , history current Axis I Axis II mental disorder accord DSMIV ; severe depression ( Hamilton scale &gt; 17 ) . Any clinically relevant acute chronic disease could interfere patient ' safety trial , expose undue risk , could interfere study objective . History presence gastrointestinal , hepatic , renal disease condition know interfere absorption , distribution , metabolism excretion drug . Pregnant breast feeding woman . Drug abuse history drug abuse ( include alcohol ) , know drug addiction . Patients severe postural hypotension ( &gt; 20 % variability stand supine ) . The following medication forbid least one month prior visit 1 course study : NMDA receptor antagonist ( amantadine , memantine , budipine , dextromethorphan ) , medication central dopaminergic antagonist activity ( neuroleptic ) , CNS stimulants sodium valproate ( may exacerbate dyskinesia ) . Hoehn Yahr score V OFF ( wheelchairbound ) . The patient participate another study participate study within last 2 month . History epilepsy seizure . Any history significant drug allergy . A history unilateral bilateral intracranial surgical procedure Parkinson 's Disease cerebral neurosurgery ( except occur age 18 ) . History severe pathology likely recur immediately study . An inability satisfactorily discontinue studyforbidden medication .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>